Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.82 |
| ▸ | NPC1 | O15118 | 2/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.71 |
| ▸ | HPGD | P15428 | 2/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | NAMPT | P43490 | 1/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.57 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.56 |
| ▸ | CTSG | P08311 | 1/20 | 0.56 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.56 |
| ▸ | CMA1 | P23946 | 1/20 | 0.56 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.54 |
| ▸ | MLYCD | O95822 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12706065 | 0.90 | RAB9A (1.00) | RAB9ANPC1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL12366268 | 0.90 | RAB9A (1.00) | RAB9ANPC1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL27452233 | 0.90 | RAB9A (0.68) | RAB9ANPC1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL5332053 | 0.88 | MLYCD (0.68) | RAB9ANPC1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL28243626 | 0.86 | HPGD (0.71) | RAB9ANPC1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL28243627 | 0.86 | HPGD (0.71) | RAB9ANPC1ALDH1A1HPGDSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL25280005 | 0.85 | MLYCD (0.64) | RAB9ANPC1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL8526512 | 0.85 | RAB9A (0.87) | RAB9ANPC1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL8507346 | 0.85 | RAB9A (0.87) | RAB9ANPC1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL799431 | 0.85 | RAB9A (0.87) | RAB9ANPC1ALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| CN-113372568-B | Preparation method of neodymium-based or holmium-based chiral metal-organic porous crystalline material, prepared material and application thereof | 合肥工业大学 | 2022-07-22 | — | — | CN | disclosed |
| CN-113372568-A | Preparation method of neodymium-based or holmium-based chiral metal-organic porous crystalline material, prepared material and application thereof | 合肥工业大学 | 2021-09-10 | — | — | CN | disclosed |
| US-10654845-B2 | 2-(het)aryl-substituted fused bicyclic heterocycle derivatives as pesticides | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2020-05-19 | — | — | US | disclosed |
| CN-106062013-B | Catalyst composition for olefin polymerization | 沙特基础工业公司 | 2019-07-16 | — | — | CN | disclosed |
| US-20180016273-A1 | 2-(HET)ARYL-SUBSTITUTED FUSED BICYCLIC HETEROCYCLE DERIVATIVES AS PESTICIDES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-01-18 | — | — | US | disclosed |
| US-9546153-B2 | Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-17 | — | — | US | disclosed |
| EP-2922840-B1 | BICYCLIC HETEROCYCLE SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2016-12-21 | — | — | EP | disclosed |
| US-20150274696-A1 | BICYCLIC HETEROCYCLE SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-10-01 | — | — | US | disclosed |
| US-8778219-B2 | Ionic liquids for separation of olefin-paraffin mixtures | UT-BATTELLE, LLC (US) | 2014-07-15 | — | — | US | disclosed |
| US-6413979-B1 | ANTAGONISTS TO ENDOTHELINS; VASODILATORS AND BRONCHODILATORS; SYNTHESIS ROUTES; HYPERTENSION, ASTHMA, RAYNAUD'S DISEASE, RENAL AND HEART FAILURE, ANGINA, DIABETES, CEREBRAL INFARC-TION AND VASOSPASM, ARTERIOSCLEROSIS, RESTENOSIS, PROSTATISM | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-07-02 | — | — | US | disclosed |
| US-6380195-B1 | INCLUDING (METHYLENEDIOXYPHENYL)CYCLOPENTENO(1,2-B)PYRIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-04-30 | — | — | US | disclosed |
| EP-1179525-A1 | Process for the preparation of carboxylic acid amides by oxidation of aldehydes in the presence of amines | Degussa Aktiengesellschaft (DE) | 2002-02-13 | — | — | EP | disclosed |
| EP-0714897-B1 | FUSED HETEROAROMATIC CYCLOPENTENE DERIVATIVE HAVING ENDOTHELIN-ANTAGONIST ACTIVITY | BANYU PHARMA CO LTD (JP) | 2001-02-14 | — | — | EP | disclosed |
| EP-1049691-A1 | SUBSTITUTED 5-(2,2-DIFLUORO-1,3-BENZODIOXOL-5-YL) CYCLOPENTENOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2000-11-08 | — | — | EP | disclosed |
| US-6087360-A | TREATING PATIENTS WITH ENDOTHELIN RELATED DISORDERS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2000-07-11 | — | — | US | disclosed |
| WO-1999037639-A1 | SUBSTITUTED 5-(2,2-DIFLUORO-1,3-BENZODIOXOL-5-YL) CYCLOPENTENOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-07-29 | — | — | WO | disclosed |
| US-5834483-A | Method of treating heart failure with endothelin antagonists | MERCK & CO., INC. (US) | 1998-11-10 | — | — | US | disclosed |
| US-5714479-A | TREATMENT OF HYPERTENSION, ACUTE RENAL FAILURE, ANGINA PECTORIS, ARTERIOSCLEROSIS, ASTHMA, GASTRIC ULCER AND SIMILAR AILMENTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1998-02-03 | — | — | US | disclosed |
| EP-0714897-A1 | FUSED HETEROAROMATIC CYCLOPENTENE DERIVATIVE HAVING ENDOTHELIN-ANTAGONIST ACTIVITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1996-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016273-A1 | 2-(HET)ARYL-SUBSTITUTED FUSED BICYCLIC HETEROCYCLE DERIVATIVES AS PESTICIDES | CYP4B1, CYP1B1, CYP8B1 | RAB9A 751/4885NPC1 2598/4885ALDH1A1 363/4885 |
| US-20150274696-A1 | BICYCLIC HETEROCYCLE SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | IRAK4, IRAK1, IRAK3 | RAB9A 2555/4885NPC1 3964/4885ALDH1A1 3540/4885 |
| US-10654845-B2 | 2-(het)aryl-substituted fused bicyclic heterocycle derivatives as pesticides | CYP4B1, CYP1B1, CYP8B1 | RAB9A 802/4885NPC1 2651/4885ALDH1A1 380/4885 |
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | RAB9A 3984/4885NPC1 4238/4885ALDH1A1 2465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.